News | February 18, 2022
Bayer raises peak sales for Nubeqa to exceed €3 billion
Darolutamide is developed jointly by Bayer and Orion Corporation
Darolutamide is developed jointly by Bayer and Orion Corporation
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector
Subscribe To Our Newsletter & Stay Updated
